🚨 JUST IN: $INO
Inovio wins FDA accelerated approval of VOCERYQ, first U.S.-approved DNA medicine, for RRP
#SEC #stocks #investing #INO #Regulatory
🔗 secwatch.observer
Inovio wins FDA accelerated approval of VOCERYQ, first U.S.-approved DNA medicine, for RRP
#SEC #stocks #investing #INO #Regulatory
🔗 secwatch.observer
November 2, 2026 at 1:04 PM
🚨 JUST IN: $INO
Inovio wins FDA accelerated approval of VOCERYQ, first U.S.-approved DNA medicine, for RRP
#SEC #stocks #investing #INO #Regulatory
🔗 secwatch.observer
Inovio wins FDA accelerated approval of VOCERYQ, first U.S.-approved DNA medicine, for RRP
#SEC #stocks #investing #INO #Regulatory
🔗 secwatch.observer
INOVIO Receives FDA Fast-Track Approval for VOCERYQ™: A New Hope for RRP Patients#United_States#INOVIO#Plymouth_Meeting#RRP#Voceryq
INOVIO Receives FDA Fast-Track Approval for VOCERYQ™: A New Hope for RRP Patients
INOVIO Pharmaceuticals announces the FDA's accelerated approval for VOCERYQ™, a groundbreaking immunotherapy aimed at reducing surgeries for adults with recurrent respiratory papillomatosis.
third-news.com
October 30, 2026 at 10:17 PM
INOVIO Receives FDA Fast-Track Approval for VOCERYQ™: A New Hope for RRP Patients#United_States#INOVIO#Plymouth_Meeting#RRP#Voceryq
#$INO VOCERYQ receives FDA accelerated approval as the first DNA medicine in the US, reducing surgery frequency in adults with recurrent respiratory papillomatosis. notreload.xyz/xy/ino-vocer...
VOCERYQ Becomes First FDA-Approved DNA Medicine for RRP
INOVIO’s VOCERYQ receives FDA accelerated approval as the first DNA medicine in the US, reducing surgery frequency in adults with recurrent respiratory papillomatosis.
notreload.xyz
November 2, 2026 at 10:40 AM
#$INO VOCERYQ receives FDA accelerated approval as the first DNA medicine in the US, reducing surgery frequency in adults with recurrent respiratory papillomatosis. notreload.xyz/xy/ino-vocer...
FDA approves Inovio's Voceryq for a rare throat disease (RRP). Stock tripled after hours, but 7 of 26 patients went a year without surgery and the trial had no control arm. https://thisnewsroom.com/inovio-voceryq-fda-approval-rare-throat-disease/
October 31, 2026 at 6:50 AM
FDA approves Inovio's Voceryq for a rare throat disease (RRP). Stock tripled after hours, but 7 of 26 patients went a year without surgery and the trial had no control arm. https://thisnewsroom.com/inovio-voceryq-fda-approval-rare-throat-disease/
Inovio's stock price more than tripled in the first few hours of trading Monday after securing FDA approval for its new drug Voceryq.
Montco biotech sets price for first approved drug at $115,000 per dose
Inovio's stock price more than tripled in the first few hours of trading Monday after securing FDA approval for its new drug Voceryq.
bit.ly
November 3, 2026 at 12:00 AM
Inovio's stock price more than tripled in the first few hours of trading Monday after securing FDA approval for its new drug Voceryq.
#InovioPharma's plasmid DNA-based immunotherapy #Voceryq has been approved in the #US for adults with #recurrentrespiratorypapillomatosis (RRP) – a first for a drug of this type.
pharmaphorum.com/news/inovio-...
pharmaphorum.com/news/inovio-...
Inovio stock rises 2.5-fold on plasmid DNA drug approval
Inovio Pharma's plasmid DNA-based Voceryq has become the second drug approved in the US for adults with recurrent respiratory papillomatosis.
pharmaphorum.com
November 2, 2026 at 9:51 AM
#InovioPharma's plasmid DNA-based immunotherapy #Voceryq has been approved in the #US for adults with #recurrentrespiratorypapillomatosis (RRP) – a first for a drug of this type.
pharmaphorum.com/news/inovio-...
pharmaphorum.com/news/inovio-...
The FDA granted accelerated approval to doruxapapogene ralaplasmid and lalikinogene sifuplasmid (Voceryq) to reduce the frequency of surgical papilloma excisions in adults with RRP, the agency announced late on Friday.
https://www.medpagetoday.com/infectiousdisease/generalinfectiousdisease/123695
https://www.medpagetoday.com/infectiousdisease/generalinfectiousdisease/123695
Novel Therapy Lands Speedy Approval for Wart-Like Airway Disease
Plasmid DNA-based immunotherapy reduced surgery need in recurrent respiratory papillomatosis
www.medpagetoday.com
November 3, 2026 at 4:37 PM
The FDA granted accelerated approval to doruxapapogene ralaplasmid and lalikinogene sifuplasmid (Voceryq) to reduce the frequency of surgical papilloma excisions in adults with RRP, the agency announced late on Friday.
https://www.medpagetoday.com/infectiousdisease/generalinfectiousdisease/123695
https://www.medpagetoday.com/infectiousdisease/generalinfectiousdisease/123695
Inovio's stock price more than tripled in the first few hours of trading Monday after securing FDA approval for its new drug Voceryq.
Montco biotech sets price for first approved drug at $115,000 per dose
Inovio's stock price more than tripled in the first few hours of trading Monday after securing FDA approval for its new drug Voceryq.
bit.ly
November 2, 2026 at 6:00 PM
Inovio's stock price more than tripled in the first few hours of trading Monday after securing FDA approval for its new drug Voceryq.
The U.S. Food and Drug Administration today granted accelerated approval for Voceryq to treat adults with recurrent respiratory papillomatosis.
#Health
#Health
FDA grants accelerated approval for first plasmid DNA-based immunotherapy for adults
The U.S. Food and Drug Administration granted accelerated approval for Voceryq to treat adults with recurrent respiratory papillomatosis.
unitedstatestribune.com
October 30, 2026 at 10:42 PM
The U.S. Food and Drug Administration today granted accelerated approval for Voceryq to treat adults with recurrent respiratory papillomatosis.
#Health
#Health
For adults with recurrent respiratory papillomatosis, airway growths can return repeatedly. The FDA’s accelerated approval of Voceryq adds a new treatment option for this rare condition.
A new option for adults facing repeated airway growths
The FDA has granted accelerated approval to Voceryq for adults with recurrent respiratory papillomatosis, a rare disease that can cause repeated airway growths.
imedic.health
November 1, 2026 at 1:51 PM
For adults with recurrent respiratory papillomatosis, airway growths can return repeatedly. The FDA’s accelerated approval of Voceryq adds a new treatment option for this rare condition.
Landmark biotech catalyst alert! Inovio Pharmaceuticals secures historic FDA accelerated approval for its very first product, Voceryq, fundamentally reshaping market sentiment and high-beta equity dynamics. As retail and institutional trade
Inovio Pharmaceuticals gets FDA approval for first product
Click here for professional Exness trading insights.
eslammsd-daily-deals-us.static.hf.space
October 31, 2026 at 12:09 AM
Landmark biotech catalyst alert! Inovio Pharmaceuticals secures historic FDA accelerated approval for its very first product, Voceryq, fundamentally reshaping market sentiment and high-beta equity dynamics. As retail and institutional trade
$INO gets FDA nod for VOCERYQ, the first US-approved DNA med, after 27% complete response rate; launch expected Q1 2027.
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
Pre-Market Updates 11/02/26
export-download.canva.com
November 2, 2026 at 1:40 PM
$INO gets FDA nod for VOCERYQ, the first US-approved DNA med, after 27% complete response rate; launch expected Q1 2027.
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
The FDA has granted accelerated approval to #Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), the first plasmid DNA-based immunotherapy approved in the US, for adults with recurrent respiratory papillomatosis (RRP).
November 2, 2026 at 9:00 AM
The FDA has granted accelerated approval to #Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), the first plasmid DNA-based immunotherapy approved in the US, for adults with recurrent respiratory papillomatosis (RRP).
DNA immunotherapy offers a break from repeated throat surgery. On 30 October, the US FDA approved Voceryq, the first plasmid DNA-based immunotherapy for recurrent respiratory papillomatosis caused by HPV.
October 31, 2026 at 6:43 PM
DNA immunotherapy offers a break from repeated throat surgery. On 30 October, the US FDA approved Voceryq, the first plasmid DNA-based immunotherapy for recurrent respiratory papillomatosis caused by HPV.
New option for a rare airway disease: the FDA has granted accelerated approval to Voceryq. It is not a cure, and a confirmatory study is required. Should access come before all long-term evidence is in?
scoldy.com/backend/p/2144
scoldy.com/backend/p/2144
health on Scoldy
FDA Approves New Treatment for Rare Airway Disease
The U.S. Food and Drug Administration has granted accelerated approval to Inovio Pharmaceuticals’ Voceryq for recurrent respiratory papillomatosis, ...
scoldy.com
November 1, 2026 at 9:39 PM
New option for a rare airway disease: the FDA has granted accelerated approval to Voceryq. It is not a cure, and a confirmatory study is required. Should access come before all long-term evidence is in?
scoldy.com/backend/p/2144
scoldy.com/backend/p/2144
Description: The U.S. Food and Drug Administration today granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP).
October 31, 2026 at 5:00 AM
Description: The U.S. Food and Drug Administration today granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP).
The FDA just approved America's first plasmid DNA immunotherapy, and it cut surgical need in a small trial. FDA Approves Inovio's Voceryq as First US Plasmid DNA Immunotherapy for Recurrent Respiratory Papillomatosis
November 1, 2026 at 9:30 PM
The FDA just approved America's first plasmid DNA immunotherapy, and it cut surgical need in a small trial. FDA Approves Inovio's Voceryq as First US Plasmid DNA Immunotherapy for Recurrent Respiratory Papillomatosis
#$INO weekly close $0.60 (-32.9% w/w), below SMA50 $1.14 / below SMA200 $1.26, RSI 27.2. Support $0.60, resistance $1.21.
Oct 30, post-close: FDA accelerated approval for VOCERYQ (RRP).
New hub updated: www.merlintrader.com/inovio-pharm...
Oct 30, post-close: FDA accelerated approval for VOCERYQ (RRP).
New hub updated: www.merlintrader.com/inovio-pharm...
October 31, 2026 at 12:24 PM
#$INO weekly close $0.60 (-32.9% w/w), below SMA50 $1.14 / below SMA200 $1.26, RSI 27.2. Support $0.60, resistance $1.21.
Oct 30, post-close: FDA accelerated approval for VOCERYQ (RRP).
New hub updated: www.merlintrader.com/inovio-pharm...
Oct 30, post-close: FDA accelerated approval for VOCERYQ (RRP).
New hub updated: www.merlintrader.com/inovio-pharm...
The FDA approved Voceryq, the first plasmid DNA-based immunotherapy cleared in the US, for the rare HPV airway disease RRP on 30 October 2026, after a trial found 7 of 26 adults with frequent prior surgery went a year without needing another operation.
November 3, 2026 at 10:22 AM
The FDA approved Voceryq, the first plasmid DNA-based immunotherapy cleared in the US, for the rare HPV airway disease RRP on 30 October 2026, after a trial found 7 of 26 adults with frequent prior surgery went a year without needing another operation.
From the company's release: accelerated approval for VOCERYQ in adults with recurrent respiratory papillomatosis. In the efficacy population, 7 of 26 patients (27%) had a complete response, meaning no surgery for 12 months. Continued approval may depend on a confirmatory study.
November 2, 2026 at 4:12 PM
From the company's release: accelerated approval for VOCERYQ in adults with recurrent respiratory papillomatosis. In the efficacy population, 7 of 26 patients (27%) had a complete response, meaning no surgery for 12 months. Continued approval may depend on a confirmatory study.
#INO INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent R…
https://www.stocktitan.net/news/INO/inovio-announces-fda-accelerated-approval-of-voceryqtm-an-6o64cas5rrns.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/INO/inovio-announces-fda-accelerated-approval-of-voceryqtm-an-6o64cas5rrns.html?utm_source=stocktitan-bluesky&utm_medium=social
INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 30, 2026 at 10:02 PM
#INO INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent R…
https://www.stocktitan.net/news/INO/inovio-announces-fda-accelerated-approval-of-voceryqtm-an-6o64cas5rrns.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/INO/inovio-announces-fda-accelerated-approval-of-voceryqtm-an-6o64cas5rrns.html?utm_source=stocktitan-bluesky&utm_medium=social
A second treatment for a rare airway disease, approved on a smaller trial than the first. The FDA gave Voceryq accelerated approval on October 30 for adults with recurrent respiratory papillomatosis, and 27% of patients in its trial went a year without surgery. 🧵
November 2, 2026 at 2:51 AM
A second treatment for a rare airway disease, approved on a smaller trial than the first. The FDA gave Voceryq accelerated approval on October 30 for adults with recurrent respiratory papillomatosis, and 27% of patients in its trial went a year without surgery. 🧵